Get the Stockscreener App
3.01
1.63%
-0.05
Sana Biotechnology Inc stock is traded at $3.01, with a volume of 2.22M.
It is down -1.63% in the last 24 hours and up +3.08% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
See More
Previous Close:
$3.06
Open:
$3.1
24h Volume:
2.22M
Relative Volume:
0.35
Market Cap:
$672.04M
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-2.0476
EPS:
-1.47
Net Cash Flow:
$-273.61M
1W Performance:
-4.75%
1M Performance:
+3.08%
6M Performance:
-43.21%
1Y Performance:
-62.33%
1-Day Range:
$2.98
$3.145
1-Week Range:
$2.98
$3.3501
52-Week Range:
$1.52
$12.00
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SANA
Sana Biotechnology Inc
|
3.01 | 672.04M | 0 | -283.26M | -273.61M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Upgrade | TD Cowen | Hold → Buy |
| Nov-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-26-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 9.8%Should You Buy? - MarketBeat
Metalpha Technology Holding And 2 Other US Penny Stocks To Monitor - Simply Wall St
Layoff Tracker: Encoded Lays Off 29% of Employees - BioSpace
11 Stocks Jeff Bezos Is Buying | Investing - U.S News & World Report Money
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 7.5%Here's What Happened - MarketBeat
146,491 Shares in Sana Biotechnology, Inc. (NASDAQ:SANA) Purchased by SG Americas Securities LLC - MarketBeat
SG Americas Securities LLC Buys New Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana Biotechnology (NASDAQ:SANA) Trading Down 6.2%Here's Why - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Trading Up 8.8%What's Next? - MarketBeat
Vanguard Group Inc. Reduces Stake in Sana Biotechnology Inc. - GuruFocus.com
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why - Asianet Newsable
Sana Biotechnology, Inc. (SANA): A Bull Case Theory - MSN
Sana Biotechnology (NASDAQ:SANA) Shares Up 13.9%Time to Buy? - MarketBeat
Flagship Pioneering, Cambridge University Health Partners, and Milner Therapeutics Institute Announce Collaboration to Accelerate Biotech Research and Innovation - Quantisnow
Sana Biotech extends rally as Morgan Stanley cites platform's potential - MSN
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Sana Biotechnology (NASDAQ:SANA) Trading Down 6.5%Here's Why - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Trading 13.9% HigherHere's Why - MarketBeat
Is Sana Biotechnology, Inc. (SANA) the Hottest Smid-Cap Stock So Far In 2025? - MSN
There May Still Be Time to Get in on These 3 Trending Biotechs - MarketBeat
Sana Biotechnology Inc (SANA-Q) QuotePress Release - The Globe and Mail
JPMorgan Chase & Co. Cuts Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA) - Defense World
Sana stock rallies 280% on pancreatic cell transplant study - MSN
Sana Biotechnology (NASDAQ:SANA) Shares Gap DownShould You Sell? - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Trading Down 5.5%Here's Why - MarketBeat
As researchers push for a type 1 diabetes cure, Sana Biotechnology provides a nudge forward - STAT
Sana Biotechnology (NASDAQ:SANA) Shares Down 5.5%Here's What Happened - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Up 5.7%Here's Why - MarketBeat
Sana Biotechnology price target raised to $12 from $9 at Morgan Stanley - MSN
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data - MSN
Sana Biotechnology (NASDAQ:SANA) Shares Up 5.7%Time to Buy? - MarketBeat
This Biotech Penny Stock Is Up 120% This Year. Analysts Think It Can Still Triple From Here in 2025. - MSN
Sana Biotechnology Shows Promise with Hypoimmune Platform - TipRanks
Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Barclays PLC - MarketBeat
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):